| Patents for A61P 27 - Drugs for disorders of the senses (53,017) |
|---|
| 05/29/2001 | US6238900 Nucleotide sequence coding enzymatic polypeptide; for the prevention of bacterial infections; bactericides |
| 05/29/2001 | US6238882 Nucleotide sequence from streptococcus; diagnosis; drug screening for new bactericides; primers; probes; antibodies; vaccines |
| 05/25/2001 | WO2001036604A2 Nucleic acids encoding endotheliases, endotheliases and uses thereof |
| 05/25/2001 | WO2001036454A1 Compositions and methods for counteracting effects of reactive oxygen species and free radicals |
| 05/25/2001 | WO2001036451A1 Vitamin e derivatives |
| 05/25/2001 | WO2001036450A1 S-allylmercaptoglutathione and uses thereof |
| 05/25/2001 | WO2001036420A1 Tricyclic azaindolizine derivatives having an spla2- inhibiting effect |
| 05/25/2001 | WO2001036374A2 Bis-basic compounds for use as tryptase inhibitors, method for producing the same and their use as medicaments |
| 05/25/2001 | WO2001036005A2 Targeted delivery of therapeutic and diagnostic moieties |
| 05/25/2001 | WO2001035962A1 Solutions containing epinastine |
| 05/25/2001 | WO2001035960A1 Use of substituted 4-(quinolin 2-yl-methoxy)phenyl-acetic acid derivatives for the treatment of diseases |
| 05/25/2001 | WO2001035948A2 Neurophilin ligands for treating ocular conditions |
| 05/25/2001 | WO2001035936A2 Use of substituted (quinolin-2-yl-methoxy)phenyl-acyl-sulphonamides and -cyanamides for the treatment of diseases |
| 05/25/2001 | WO2001007023A3 Azetidine compounds in cns and eye diseases |
| 05/25/2001 | CA2391969A1 S-allylmercaptoglutathione and uses thereof |
| 05/25/2001 | CA2391450A1 Targeted delivery of therapeutic and diagnostic moieties |
| 05/25/2001 | CA2386579A1 Neurophilin ligands for treating ocular conditions |
| 05/23/2001 | EP1100913A1 Mekk1 serine threonine kinases -interacting fha forkhead associated domain protein 1 (mif1) |
| 05/23/2001 | EP1100909A2 Dna replication- and repair-associated proteins |
| 05/23/2001 | EP1100907A2 Human cytoskeletal proteins |
| 05/23/2001 | EP1100896A1 Dna encoding snorf33 receptor |
| 05/23/2001 | EP1100894A2 Short oligonucleotides for the inhibition of vegf expression |
| 05/23/2001 | EP1100869A1 98 human secreted proteins |
| 05/23/2001 | EP1100814A2 Inhibitors of urokinase and blood vessel formation |
| 05/23/2001 | EP1100813A1 HUMAN BOMBESIN RECEPTOR SUBTYPE-3sb |
| 05/23/2001 | EP1100807A1 STEREOISOMERS OF CpG OLIGONUCLEOTIDES AND RELATED METHODS |
| 05/23/2001 | EP1100797A1 Heterocyclic compounds as inhibitors of rotamase enzymes |
| 05/23/2001 | EP1100792A1 Tricyclic sulfonamides and their derivatives as inhibitors of matrix metalloproteinases |
| 05/23/2001 | EP1100790A1 Antidiabetic piperazine derivatives, processes for their preparation and compositions containing them |
| 05/23/2001 | EP1100547A1 Compositions and methods for the treatment and diagnosis of cardiovascular disease |
| 05/23/2001 | EP1100524A2 Use of recombinant human uteroglobin in treatment of inflammatory and fibrotic conditions |
| 05/23/2001 | EP1100519A1 Multibinding agents that modulate nmda receptors |
| 05/23/2001 | EP1100506A1 Integrin receptor antagonists |
| 05/23/2001 | EP1100493A1 INDOLE sPLA 2? INHIBITORS |
| 05/23/2001 | EP1100491A1 Ophthalmic compositions for treating ocular hypertension |
| 05/23/2001 | EP1100480A2 Cholinergic agents in the treatment of presbyopia |
| 05/23/2001 | EP1100462A2 Methods of ophthalmic administration |
| 05/23/2001 | EP0900218A4 Heterocyclic compounds |
| 05/23/2001 | EP0750614B1 Quinazolinyl-amino derivatives having alpha-antagonist activity |
| 05/23/2001 | DE19955476A1 Bis-basische Verbindungen als Tryptase-Inhibitoren, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel Bis-basic compounds as tryptase inhibitors, to processes for their preparation and their use as medicaments |
| 05/23/2001 | CN1296488A Bicycle hydroxamic acid derivatives |
| 05/23/2001 | CN1296485A Substituted indolealkanoic acids |
| 05/23/2001 | CN1296481A (4-arylsulfonylamino)-tetrahydropyran-4-carboxylic acid hydroxamides |
| 05/23/2001 | CN1296474A Process for alkylating hindered sulfonamides useful in the production of matrix metalloproteinase inhibitors |
| 05/22/2001 | US6235877 Peptido-mimetic compounds containing RGD sequence useful as integrin inhibitors |
| 05/22/2001 | US6235779 Use of cis-Δ4 analogs of prostaglandins as ocular hypotensives |
| 05/22/2001 | US6235756 Methods and compositions for inhibition of angiogenesis by thalidomide |
| 05/22/2001 | US6235750 Nitric oxide synthase inhibitor |
| 05/22/2001 | US6235747 6-phenyl-pyridin-2-ylamine derivatives |
| 05/22/2001 | US6235742 5-substituted pyrazolo[4,3-D]pyrimidin-7-ones |
| 05/22/2001 | US6235732 Neurokinin antagonists |
| 05/22/2001 | US6235285 An isolated polypeptide comprising a heterologous amino acid sequence fused to specific polynucleotide sequence |
| 05/22/2001 | CA2217006C Novel substituted piperazine derivatives having tachykinin receptor antagonists activity |
| 05/17/2001 | WO2001034805A2 Human vanilloid receptor gene |
| 05/17/2001 | WO2001034768A2 15 human secreted proteins |
| 05/17/2001 | WO2001034767A2 22 human secreted proteins |
| 05/17/2001 | WO2001034643A1 24 human secreted proteins |
| 05/17/2001 | WO2001034629A1 21 human secreted proteins |
| 05/17/2001 | WO2001034628A1 35 human secreted proteins |
| 05/17/2001 | WO2001034627A1 28 human secreted proteins |
| 05/17/2001 | WO2001034623A1 29 human secreted proteins |
| 05/17/2001 | WO2001034615A1 Phospholipids of hydroxyeicosatetraenoic acid-like derivatives |
| 05/17/2001 | WO2001034607A1 Pdgf receptor kinase inhibitory compounds, their preparation, purification and pharmaceutical compositions including same |
| 05/17/2001 | WO2001034586A2 Branched adamantyl and noradamantyl aryl- and aralkylpiperazines with serotonin 5-ht1a activity |
| 05/17/2001 | WO2001034572A2 Carboxamide-substituted benzimidazol derivatives, method for the production thereof and their use as tryptase inhibitors |
| 05/17/2001 | WO2001034554A1 Compositions containing hydroxyeicosatetraenoic acid derivatives and methods of use in treating dry eye disorders |
| 05/17/2001 | WO2001034553A2 2,2-difluoro 15-hydroxyeicosatetraenoic acid analogs and methods of use |
| 05/17/2001 | WO2001034552A2 Benzenoid derivatives of 15-hydroxyeicosatetraenoic acid and methods of their use in treating dry eye disorders |
| 05/17/2001 | WO2001034551A1 Hydroxyeicosatetraenoic acid analogs and methods of their use in treating dry eye disorders |
| 05/17/2001 | WO2001034550A2 15-hydroxyeicosatetraenoic acid analogs with enhanced metabolic stability and methods of their use in treating dry eye disorders |
| 05/17/2001 | WO2001034549A1 Hydroxyeicosatetraenoate salts, compositions and methods of use in treating dry eye disorders |
| 05/17/2001 | WO2001034548A2 3-heteroatom substituted and two carbon homologs of 15-hete and methods of use |
| 05/17/2001 | WO2001034547A2 15-hydroxyeicosatetraenoic acid-related compounds and methods of use |
| 05/17/2001 | WO2001034546A2 Omega chain modified 15-hydroxyeicosatetraenoic acid derivatives and methods of their use for the treatment of dry eye |
| 05/17/2001 | WO2001034183A2 Use of caspase-14 and caspase-14 modulators to diagnose and/or treat skin, eye and brain disorders |
| 05/17/2001 | WO2001034144A1 Lipoxin a4 and its analogs for the treatment of dry eye |
| 05/17/2001 | WO2001034136A2 Use of adatanserin for the treatment of neurodegenerative conditions |
| 05/17/2001 | WO2001034129A2 Heteroatom-interrupted analogs of 15-hydroxyeicosatetraenoic acid and methods of use |
| 05/17/2001 | WO2001022955A3 Novel combination of loteprednol and antihistamines |
| 05/17/2001 | WO2001018043A3 Neurogenic compositions and methods |
| 05/17/2001 | WO2001012598A9 METHODS OF INHIBITING BINDING OF β-SHEET FIBRIL TO RAGE AND CONSEQUENCES THEREOF |
| 05/17/2001 | WO2001007471A9 Cell cycle and proliferation proteins |
| 05/17/2001 | WO2000076499A3 Neuroprotective and retinoprotective ophthalmologic medicines |
| 05/17/2001 | US20010001309 For treating pathologies related to altered alpha v beta 3 integrin-mediated cell attachment, in particular wherein inhibition of angiogenesis is desired, for example in tumors, also associated with metastasis |
| 05/17/2001 | DE19954516A1 Epinastin-haltige Lösungen Epinastine-containing solutions |
| 05/17/2001 | DE19953899A1 Carboxamid-substituierte Benzimidazolderivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel Carboxamide-substituted benzimidazole derivatives, processes for their preparation and their use as medicaments |
| 05/17/2001 | CA2428827A1 Human vanilloid receptor gene |
| 05/17/2001 | CA2390797A1 Methods for the treatment and prevention of neurodegenerative conditions |
| 05/17/2001 | CA2390524A1 Branched adamantyl and noradamantyl aryl- and aralkylpiperazines with serotonin 5-ht1a activity |
| 05/17/2001 | CA2390510A1 Use of caspase-14 and caspase-14 modulators to diagnose and/or treat skin, eye and brain disorders |
| 05/17/2001 | CA2390421A1 24 human secreted proteins |
| 05/17/2001 | CA2389724A1 28 human secreted proteins |
| 05/17/2001 | CA2389722A1 15 human secreted proteins |
| 05/17/2001 | CA2389326A1 35 human secreted proteins |
| 05/17/2001 | CA2388044A1 Hydroxyeicosatetraenoate salts, compositions and methods of use in treating dry eye disorders |
| 05/17/2001 | CA2388030A1 Benzenoid derivatives of 15-hydroxyeicosatetraenoic acid and methods of their use in treating dry eye disorders |
| 05/17/2001 | CA2388008A1 29 human secreted proteins |
| 05/17/2001 | CA2387964A1 22 human secreted proteins |
| 05/17/2001 | CA2387959A1 21 human secreted proteins |
| 05/17/2001 | CA2387624A1 Pdgf receptor kinase inhibitory compounds, their preparation, purification and pharmaceutical compositions including same |